Shares of LivaNova PLC (NASDAQ:LIVN – Get Free Report) have received a consensus rating of “Buy” from the seven analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $69.17.
Several brokerages have issued reports on LIVN. The Goldman Sachs Group assumed coverage on shares of LivaNova in a research note on Friday, October 4th. They set a “buy” rating and a $65.00 target price on the stock. Mizuho decreased their price objective on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. Robert W. Baird upped their price objective on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price objective on shares of LivaNova in a report on Monday, November 25th. Finally, Baird R W upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th.
View Our Latest Stock Analysis on LivaNova
Institutional Investors Weigh In On LivaNova
LivaNova Price Performance
Shares of NASDAQ:LIVN opened at $50.50 on Tuesday. LivaNova has a one year low of $43.15 and a one year high of $64.47. The stock has a fifty day moving average of $52.25 and a 200-day moving average of $51.94. The company has a market capitalization of $2.74 billion, a PE ratio of 120.24 and a beta of 0.98. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37.
About LivaNova
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Featured Articles
- Five stocks we like better than LivaNova
- What Investors Need to Know About Upcoming IPOs
- NVIDIA’s Blackwell Chips Set for Arizona Manufacturing by TSMC?
- ESG Stocks, What Investors Should Know
- Okta: Bullish Signals Suggest a Market Reversal Is Underway
- What Does Downgrade Mean in Investing?
- BlackRock Makes Waves With $12B Private Credit Acquisition
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.